Parameters for individualizing systemic therapy in non-small cell lung cancer

Drug Resistance Updates

Volumn 13, Issue 6, 2010, Pages 196-204

  Gadgeel, Shirish M ^a,b   Cote, Michele L ^a,b   Schwartz, Ann G ^a,b   Matherly, Larry H ^a,b   Wozniak, Antoinette ^a,b   Bepler, Gerold ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Bevacizumab; Crizotinib; EGFR; EML4 ALK; ERCC1; Lung cancer; RRM1; TS

Indexed keywords

BETA TUBULIN; BEVACIZUMAB; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; K RAS PROTEIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE 1; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; VINCA ALKALOID;

BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HYPERTENSION; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MEDICAL PARAMETERS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEOMICS; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 78650193461     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.10.001     Document Type: Article

References (88)

1. A.A. Adjei Preclinical and clinical studies with combinations of pemetrexed and gemcitabine Semin. Oncol. 29 6 Suppl 18 2002 30 34
2. R. Arriagada, B. Bergman, A. Dunant, C.T. Le, J.P. Pignon, and J. Vansteenkiste Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl. J. Med. 350 2004 351 360
3. Y. Bang, E.L. Kwak, A.T. Shaw, D.R. Camidge, A.J. Iafrate, and R.G. Maki Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) J. Clin. Oncol. 28 18 Suppl. 2010 3 (Meeting Abstracts)
4. G. Bepler, K.C. O'briant, Y.C. Kim, G. Schreiber, and D.M. Pitterle A 1.4-Mb high-resolution physical map and contig of chromosome segment 11p15.5 and genes in the LOH11A metastasis suppressor region Genomics 55 1999 164 175
5. G. Bepler, A. Gautam, L.M. McIntyre, A.F. Beck, D.S. Chervinsky, and Y.C. Kim Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer J. Clin. Oncol. 20 2002 1353 1360
6. G. Bepler, I. Kusmartseva, S. Sharma, A. Gautam, A. Cantor, and A. Sharma RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer J. Clin. Oncol. 24 2006 4731 4737
7. G. Bepler, K.E. Sommers, A. Cantor, X. Li, A. Sharma, and C. Williams Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer J. Thorac. Oncol. 3 2008 1112 1118
8. Bepler, G.; Olaussen, K.A.; Vataire, A.L.; Soria, J.C.; Zheng, Z.; Dunant, A.; et al.; ERCC1 and RRM1 in the International Adjuvant Lung Trial by automated quantitative in situ analysis. Am. J. Pathol.; in press.
9. A.M. Bergman, P.P. Eijk, V. Ruiz van Haperen, K. Smid, G. Veerman, and I. Hubeek In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant Cancer Res. 65 2005 9510 9516
10. C. Bernaards, P. Hegde, D. Chen, E. Holmgren, M. Zheng, and A.M. Jubb Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: analysis of phase III studies J. Clin. Oncol. 28 15 Suppl. 2010 10519 (Meeting Abstracts)
11. B. Besse, S.F. Lasserre, P. Compton, J. Huang, S. Augustus, and U.P. Rohr Bevacizumab safety in patients with central nervous system metastases Clin. Cancer Res. 16 2010 269 278
12. P. Bono, H. Elfving, T. Utriainen, P. Osterlund, T. Saarto, and T. Alanko Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma Ann. Oncol. 20 2009 393 394
13. F. Cappuzzo, T. Ciuleanu, L. Stelmakh, S. Cicenas, A. Szczesna, and E. Juhasz Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study Lancet Oncol. 11 2010 521 529
14. D.P. Carbone, L. Seymour, K. Ding, H. Roder, M. Tsao, and F.A. Shepherd Serum proteomic prediction of outcomes in advanced NSCLC patients treated with erlotinib/placebo in the NCIC clinical trials group BR21 trial J. Thorac. Oncol. 5 2010 203O Abstract
15. P. Ceppi, M. Volante, S. Saviozzi, I. Rapa, S. Novello, and A. Cambieri Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Cancer 107 2006 1589 1596
16. K. Chansky, F.C. Mack, J.J. Crowley, P.N. Lara, F.R. Hirsch, and W.A. Franklin Chemotherapy outcomes by histologic subtype of non-small cell lung cancer (NSCLC): analysis of the SWOG database for antimicrotubule-platinum therapy J. Thorac. Oncol. 4 2009 B2.7 Abstract
17. T. Ciuleanu, T. Brodowicz, C. Zielinski, J.H. Kim, M. Krzakowski, and E. Laack Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study Lancet 374 2009 1432 1440
18. M. Cobo, D. Isla, B. Massuti, A. Montes, J.M. Sanchez, and M. Provencio Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer J. Clin. Oncol. 25 2007 2747 2754
19. G. D'Addario, M. Pintilie, N.B. Leighl, R. Feld, T. Cerny, and F.A. Shepherd Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature J. Clin. Oncol. 23 2005 2926 2936
20. S.E. Dahlberg, A.B. Sandler, J.R. Brahmer, J.H. Schiller, and D.H. Johnson Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J. Clin. Oncol. 28 2010 949 954
21. J.D. Davidson, L. Ma, M. Flagella, S. Geeganage, L.M. Gelbert, and C.A. Slapak An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines Cancer Res. 64 2004 3761 3766
22. J.Y. Douillard, F.A. Shepherd, V. Hirsh, T. Mok, M.A. Socinski, and R. Gervais Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J. Clin. Oncol. 28 2010 744 752
23. A. Dowlati, R. Gray, A.B. Sandler, J.H. Schiller, and D.H. Johnson Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizuma-an Eastern Cooperative Oncology Group Study Clin. Cancer Res. 14 2008 1407 1412
24. L.K. Dunnwald, M.A. Rossing, and C.I. Li Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients Breast Cancer Res. 9 2007 R6
25. D.R. Gandara, P.P. Grimminger, P.C. Mack, P.V. Danenberg, P. Lara Jr.; and K.D. Danenberg Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy J. Clin. Oncol. 28 15 Suppl 2010 7513 (Meeting Abstracts)
26. A. Gautam, and G. Bepler Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase Cancer Res. 66 2006 6497 6502
27. A. Gautam, Z.R. Li, and G. Bepler RRM1-induced metastasis suppression through PTEN-regulated pathways Oncogene 22 2003 2135 2142
28. A.F. Gazdar DNA repair and survival in lung cancer-the two faces of Janus N Engl. J. Med. 356 2007 771 773
29. N. Hanna, F.A. Shepherd, F.V. Fossella, J.R. Pereira, M.F. De, and P.J. von Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J. Clin. Oncol. 22 2004 1589 1597
30. H. Hashimoto, Y. Ozeki, M. Sato, K. Obara, N. Matsutani, and Y. Nakagishi Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung Cancer 106 2006 1595 1601
31. M. Huncharek, J. Muscat, and J.F. Geschwind K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases Carcinogenesis 20 1999 1507 1510
32. D.H. Johnson, L. Fehrenbacher, W.F. Novotny, R.S. Herbst, J.J. Nemunaitis, and D.M. Jablons Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J. Clin. Oncol. 22 2004 2184 2191
33. R.D. Kennedy, J.E. Quinn, P.B. Mullan, P.G. Johnston, and D.P. Harkin The role of BRCA1 in the cellular response to chemotherapy J. Natl. Cancer Inst. 96 2004 1659 1668
34. C.N. Lee, H.Y. Chen, and H.E. Liu Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations J. Clin. Oncol. 28 2010 e111 e112
35. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl. J. Med. 350 2004 2129 2139
36. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, and H. Isobe Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl. J. Med. 362 2010 2380 2388
37. E. Massarelli, M. Varella-Garcia, X. Tang, A.C. Xavier, N.C. Ozburn, and D.D. Liu KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin. Cancer Res. 13 2007 2890 2896
38. L.G. Mendelsohn, C. Shih, V.J. Chen, L.L. Habeck, S.B. Gates, and K.A. Shackelford Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis Semin. Oncol. 26 2 Suppl 6 1999 42 47
39. Y. Miki, J. Swensen, D. Shattuck-Eidens, P.A. Futreal, K. Harshman, and S. Tavtigian A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 1994 66 71 (Pubitemid 24345325)
40. V.A. Miller, M.G. Kris, N. Shah, J. Patel, C. Azzoli, and J. Gomez Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J. Clin. Oncol. 22 2004 1103 1109
41. T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, and J. Tsurutani Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial Lancet Oncol. 11 2010 121 128
42. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl. J. Med. 361 2009 947 957
43. M. Monzo, R. Rosell, J.J. Sanchez, J.S. Lee, A. O'Brate, and J.L. Gonzalez-Larriba Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations J. Clin. Oncol. 17 1999 1786 1793
44. P.B. Mullan, J.E. Quinn, P.M. Gilmore, S. McWilliams, H. Andrews, and C. Gervin BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents Oncogene 20 2001 6123 6131
45. T. Nakagawa, Y. Otake, K. Yanagihara, R. Miyahara, S. Ishikawa, and M. Fukushima Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC) Lung Cancer 43 2004 145 149 (Pubitemid 38114742)
46. K.A. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. Andre, and V. Haddad DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl. J. Med. 355 2006 983 991
47. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
48. S.J. Payne, R.L. Bowen, J.L. Jones, and C.A. Wells Predictive markers in breast cancer-the present Histopathology 52 2008 82 90
49. M. Pesek, L. Benesova, B. Belsanova, P. Mukensnabl, F. Bruha, and M. Minarik Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status Anticancer Res. 29 2009 2767 2773
50. D.M. Pitterle, Y.C. Kim, E.M. Jolicoeur, Y. Cao, K.C. O'briant, and G. Bepler Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1) Mamm. Genome 10 1999 916 922
51. A. Potti, H.K. Dressman, A. Bild, R.F. Riedel, G. Chan, and R. Sayer Genomic signatures to guide the use of chemotherapeutics Nat. Med. 12 2006 1294 1300
52. J.E. Quinn, R.D. Kennedy, P.B. Mullan, P.M. Gilmore, M. Carty, and P.G. Johnston BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis Cancer Res. 63 2003 6221 6228
53. A.C. Racanelli, S.B. Rothbart, C.L. Heyer, and R.G. Moran Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation. AMPK activation, and mammalian target of rapamycin inhibition Cancer Res. 69 2009 5467 5474
54. C. Reynolds, C. Obasaju, M.J. Schell, X. Li, Z. Zheng, and D. Boulware Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer J. Clin. Oncol. 27 2009 5808 5815
55. R. Rosell, K.D. Danenberg, V. Alberola, G. Bepler, J.J. Sanchez, and C. Camps Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin. Cancer Res. 10 2004 1318 1325
56. R. Rosell, L. Perez-Roca, J.J. Sanchez, M. Cobo, T. Moran, and I. Chaib Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression PLoS One 4 2009 e5133
57. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, and C. Camps Screening for epidermal growth factor receptor mutations in lung cancer N Engl J. Med. 361 2009 958 967
58. S.E. Salmon, A.W. Hamburger, B. Soehnlen, B.G. Durie, D.S. Alberts, and T.E. Moon Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs N Engl. J. Med. 298 1978 1321 1327 (Pubitemid 8357629)
59. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, and A. Dowlati Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl. J. Med. 355 2006 2542 2550 (Pubitemid 44917502)
60. A.B. Sandler, J.H. Schiller, R. Gray, I. Dimery, J. Brahmer, and M. Samant Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab J. Clin. Oncol. 27 2009 1405 1412
61. G.V. Scagliotti, P. Parikh, P.J. von, B. Biesma, J. Vansteenkiste, and C. Manegold Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J. Clin. Oncol. 26 2008 3543 3551
62. G. Scagliotti, N. Hanna, F. Fossella, K. Sugarman, J. Blatter, and P. Peterson The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies Oncologist 14 2009 253 263
63. J.H. Schiller, S. Adak, R.H. Feins, S.M. Keller, W.A. Fry, and R.B. Livingston Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy J. Clin. Oncol. 19 2001 448 457
64. D. Schrag, H.S. Garewal, H.J. Burstein, D.J. Samson, D.D. Von Hoff, and Somerfield MR American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays J. Clin. Oncol. 22 2004 3631 3638
65. R. Scully, A. Xie, and G. Nagaraju Molecular functions of BRCA1 in the DNA damage response Cancer Biol. Ther. 3 2004 521 527
66. L.V. Sequist, R.G. Martins, D. Spigel, S.M. Grunberg, A. Spira, and P.A. Janne First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations J. Clin. Oncol. 26 2008 2442 2449
67. P. Seve, and C. Dumontet Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9 2008 168 175
68. G.L. Shaw, A.F. Gazdar, R. Phelps, S.M. Steinberg, R.I. Linnoila, and B.E. Johnson Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer J. Cell. Biochem. 24 Suppl. 1996 173 185
69. A.T. Shaw, B. Yeap, D.B. Costa, B.J. Solomon, E.L. Kwak, and A.T. Nguyen Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer J. Clin. Oncol. 28 15 Suppl 2010 7606 (Meeting Abstracts)
70. H. Shigematsu, T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki, and H. Lee Somatic mutations of the HER2 kinase domain in lung adenocarcinomas Cancer Res. 65 2005 1642 1646
71. L.M. Sholl, Y. Xiao, V. Joshi, B.Y. Yeap, L.A. Cioffredi, and D.M. Jackman EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry Am. J. Clin. Pathol. 133 2010 922 934
72. G. Simon, A. Sharma, X. Li, T. Hazelton, F. Walsh, and C. Williams Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer J. Clin. Oncol. 25 2007 2741 2746
73. M.A. Socinski, C.J. Langer, J.E. Huang, M.M. Kolb, P. Compton, and L. Wang Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases J. Clin. Oncol. 27 2009 5255 5261
74. M. Soda, Y.L. Choi, M. Enomoto, S. Takada, Y. Yamashita, and S. Ishikawa Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
75. B. Solomon, M. Varella-Garcia, and D.R. Camidge ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer J. Thorac. Oncol. 4 2009 1450 1454
76. R. Sordella, D.W. Bell, D.A. Haber, and J. Settleman Gefitinib- sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
77. C. Su, S. Zhou, L. Zhang, S. Ren, J. Xu, and J. Zhang ERCC1 RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer Med. Oncol. 2010 10.1007/s12032-010-9553-9
78. F. Taguchi, B. Solomon, V. Gregorc, H. Roder, R. Gray, and K. Kasahara Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study J. Natl. Cancer Inst. 99 2007 838 846
79. J.L. Tonkinson, J.F. Worzalla, C.H. Teng, and L.G. Mendelsohn Cell cycle modulation by a multitargeted antifolate. LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma Cancer Res. 59 1999 3671 3676
80. M.S. Tsao, S. Viel-Ronen, K. Ding, D. Lau, N. Liu, and A. Sakurada Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer J. Clin. Oncol. 25 2007 5240 5247
81. M.S. Tsao, C. Zhu, K. Ding, D. Strumpf, M. Pintilie, and M. Meyerson A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients J. Clin. Oncol. 26 15 Suppl 2008 7510 (Meeting Abstracts)
82. L. Vroling, J.S. Lind, R.R. de Haas, and H.M. Verheul CD133+ circulating haematopoetic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients Br. J. Cancer 102 2010 268 275
83. S.E. Wang, A. Narasanna, M. Perez-Torres, B. Xiang, F.Y. Wu, and S. Yang HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors Cancer Cell 10 2006 25 38
84. J.Y. Wu, S.G. Wu, C.H. Yang, C.H. Gow, Y.L. Chang, and C.J. Yu Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response Clin. Cancer Res. 14 2008 4877 4882
85. W. Zhang, S.E. Dahlberg, D. Yang, A.B. Sandler, J.R. Brahmer, and J.H. Schiller Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599 J. Clin. Oncol. 27 15 Suppl 2009 8032 (Meeting Abstracts)
86. Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer N Engl. J. Med. 356 2007 800 808
87. Z. Zheng, X. Li, M.J. Schell, T. Chen, D. Boulware, and L. Robinson Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer Cancer 112 2008 2765 2773
88. C.Q. Zhu, S.G. da Cunha, K. Ding, A. Sakurada, J.C. Cutz, and N. Liu Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR21 J. Clin. Oncol. 26 2008 4268 4275